Background: Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a high proportion of cancer stem cells (CSC). CSCs are thought to be responsible for tumor initiation and drug resistance.
Paclitaxel-resistant MDA-MB-468 triple negative BC cells were selected via continuous treatment with 10nM paclitaxel for 5 to 7 days, at which time drug resistant cell colonies emerged. Cell viability in vitro was assessed using the Bright Glo Luciferase assay (Promega, Madison, WI, USA). 4.2...